Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
NurExone Biologic
NurExone Biologic Overview
Nurexone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.
The company is developing a revolutionary biological extracellular vesicles-based technology drug platform to treat damage in the Central Nerve System (CNS). NurExone’s novel approach to SCI treatment is based on the perspective that intranasal exosome administration has broad potential and offers an alternative to other treatments that are under development to treat SCI. Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion, Haifa in collaboration with Prof. Danny Offen from Tel Aviv University tested a novel proprietary treatment using intranasal administration of Exosomes derived from mesenchymal stem cells. Their exosomes were loaded with PTEN siRNA to target complete spinal cord lesion in rats. The research showed significant functional recovery.
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
#Public Trading #Expand
Apr 19, 2024
finance.yahoo.com
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
#Management Changes
Apr 2, 2024
finance.yahoo.com
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
#Investment
Mar 27, 2024
finance.yahoo.com
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
#Investment
Mar 22, 2024
finance.yahoo.com
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
#Public Trading #Expand
Apr 19, 2024
finance.yahoo.com
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
#Management Changes
Apr 2, 2024
finance.yahoo.com
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
#Investment
Mar 27, 2024
finance.yahoo.com
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
#Investment
Mar 22, 2024
finance.yahoo.com
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
#Partners
View other companies you might be interested in
NurExone Biologic Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.